# ANDEXXA

NDC: 0310-3200
Generic name: andexanet alfa
Labeler / Manufacturer: AstraZeneca Pharmaceuticals LP
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: Biologic License Application
Dosage form: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Routes: INTRAVENOUS
Marketing started: 20220712
Marketing ended: 20271231
FDA application: BLA125586

## Active ingredients

- ANDEXANET ALFA: 200 mg/20mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"0310-3200"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=0310-3200
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2d9d90a6-63e6-46ef-96ff-dd6519ae7b6c